Gerresheimer Indian plant to manufacture vials and ampoules

gerresheimerWith seven plants, Gerresheimer enjoys a strong position in the South East Asian market for the highly specialist manufacturing of glass and plastic products for the pharmaceutical sector. A new factory making vials and ampoules recently went on stream in Kosamba.

“We are the specialist when it comes to vials, ampoules, and cartridges,” said Jens Heymann, Senior VP of Europe & Asia Tubular Glass. “With our new plant in India and its counterparts in China, we will be able to fully meet demand from the Asian pharma industry for high-quality primary packaging made from tubular glass. Our zero-defect strategy is based on a ‘product-by-process’ approach. We want our customers to get the same high-quality products from us wherever they are in the world. Which factory they were made in cannot be allowed to have an influence.”

Vials, or injection vials as they are also known, will play a key role in Gerresheimer’s presence at this year’s CPhl trade show. They are amongst the world’s most popular pharmaceutical packaging solutions and Gerresheimer’s can hold between 1 and 50 ml. As well as its vials, the company will also be showcasing other core products including ampoules, cartridges, flasks, and more specialty products made from clear and amber borosilicate glass types I, II, and III.

Gerresheimer manufactures its primary packaging for the Asian market in Shuangfeng in China and at its new plant in the Indian city of Kosamba. The Chinese factory has 30 years experience in making vials and has been awarded a range of certificates that no other competitor in the region can match. The company supplies over 300 pharmaceutical customers in Asia, the U.S., and Eastern Europe and enjoys a leading position in the Chinese market.

Gerresheimer’s glass experts will be on hand at booth H22 at CPhI in Jakarta, which is being held at Jakarta International Expo from March 22 to 24.

Gerresheimer
gerresheimer.com

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

Speak Your Mind

*